Last reviewed · How we verify

placebo sitagliptin — Competitive Intelligence Brief

placebo sitagliptin (placebo sitagliptin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Diabetes.

marketed Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

placebo sitagliptin (placebo sitagliptin) — GlaxoSmithKline. Placebo sitagliptin is an inert formulation used as a control in clinical trials; it contains no active pharmaceutical ingredient and produces no therapeutic effect.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
placebo sitagliptin TARGET placebo sitagliptin GlaxoSmithKline marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). placebo sitagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-sitagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: